' in combination with autophagy-related proteins. We also performed a bibliographic search for the clinical impact of the autophagy process using the keywords of autophagy inhibitors such as 'bafilomycin A1', 'chloroquine', 'hydroxychloroquine', '3-Methyl Adenine (3-MA)', 'lucanthone', 'wortmannin' and autophagy activators such as 'rapamycin', 'perifosine', 'metformin' in combination with 'disease', 'treatment
, such as chloroquine (CQ) and lucanthone with conventional cancer therapeutics has been investigated in clinical trials, but adverse drug-drug interactions are a high possibility. Here we designed and synthesized a novel, small-molecule library based on an acridine skeleton and the CQ structure with various modifications and substitutions and screened the compounds for effective autophagy inhibition. We found that 9
. An investigation of structure-activity relationships revealed the substituent in the 4-position of ring A to be critical for mutagenicity. Activity was found when this group was a hydroxymethyl (i.e., HCT) or an aldehyde (Win 25,315), but the analogues having a carboxyl group (Win 25,850) or methyl group (lucanthone) in this positionwere inactive. Removal of a single ethyl group from the side chain did
geographic strains of Schistosoma mansoni were treated with one of four selected drugs and parasiticidal effects were compared.Responses to treatment were generally similar among strains except in two trials involving a Puerto Rican strain that was unusually sensitive to hycanthone and relatively resistant to stibophen.Selective killing of male worms occurred consistently with lucanthone and hycanthone
Chemotherapeutic studies on experimental Schistosoma mansoni infection of Mastomys natalensis Comparative chemotherapeutic studies on various well known or newly developed schistosomicidal agents have been carried out in Mastomys natalensis experimentally infected with Schistosoma mansoni. Hycanthone, lucanthone, niridazole, Mirasan, the experimental compounds HOE S616, HOE S683, HOE S688
Lucanthone hydrochloride: A review THIS REVIEW OF THE PUBLISHED WORK ON THE TREATMENT OF BILHARZIASIS WITH LUCANTHONE HYDROCHLORIDE DRAWS ATTENTION TO THE INCONCLUSIVE NATURE OF MANY OF THE TRIALS CARRIED OUT SO FAR: either the dosage was inadequate or the patients were not followed up for a sufficient length of time. The author stresses the importance of obtaining a high concentration of lucanthone in the body fluids. He suggests that better results might be obtained if the total dose were given in two days or even as a single, massive dose. This method might also reduce the side effects, which do not appear, as a rule, until the second or third day.
Safety and Efficacy Study of Lucanthone When Used in Combination With Temozolomide(TMZ) and Radiation to Treat Glioblastoma Multiforme(GBM) Safety and Efficacy Study of Lucanthone When Used in Combination With Temozolomide(TMZ) and Radiation to Treat Glioblastoma Multiforme(GBM) - Full Text View - ClinicalTrials.gov Try the modernized ClinicalTrials.gov beta website. Learn more about * PRS Login * Home * Search Results * Study Record DetailSaved Studies Save this study WarningYou have reached the maximum number of saved studies (100).Please remove one or more studies before adding more. Safety and Efficacy Study of Lucanthone When Used in Combination With Temozolomide(TMZ) and Radiation to Treat Glioblastoma Multiforme(GBM) The safety and scientific validity of this study
Evaluation of Lucanthone to Whole Brain Radiation Therapy in Patients With Brain Metastases From Non-Small Cell Lung Cancer Evaluation of Lucanthone to Whole Brain Radiation Therapy in Patients With Brain Metastases From Non-Small Cell Lung Cancer - Full Text View - ClinicalTrials.gov Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort. Hide glossary Record DetailSaved Studies Save this study WarningYou have reached the maximum number of saved studies (100).Please remove one or more studies before adding more. Evaluation of Lucanthone to Whole Brain Radiation Therapy in Patients With Brain Metastases From Non-Small Cell Lung Cancer The safety and scientific validity of this study is the responsibility of the study sponsor and investigators